Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

Journal of Clinical Oncology

Volumn 20, Issue 19, 2002, Pages 4083-4107

  Rizzo, J Douglas ^a   Lichtin, Alan E ^a   Woolf, Steven H ^a   Seidenfeld, Jerome ^a   Bennett, Charles L ^a   Cella, David ^a   Djulbegovic, Benjamin ^a   Goode, Matthew J ^a   Jakubowski, Ann A ^a   Lee, Stephanie J ^a   Miller, Carole B ^a   Rarick, Mark U ^a   Regan, David H ^a   Browman, George P ^a   Gordon, Michael S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HUMAN; IRON BINDING CAPACITY; IRON DEFICIENCY; IRON THERAPY; MEDICAL SOCIETY; META ANALYSIS; MYELODYSPLASIA; MYELOMA; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0036787775     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.177     Document Type: Article

References (67)

1. Agency for Health Care Policy and Research (AHCPR): AHCPR Requests Topic Nominations for Evidence Reports and Technology Assessments: Media advisory. November 28, 1997. Http://www.ahcpr.gov/news/press/epcnompr.htm, accessed October 27, 2000
2. Agency for Health Care Policy and Research (AHCPR): AHCPR Announces New Evidence Report Topics: Press release. October 29, 1998. Http://www.ahcpr.gov/news/press/epctopic.htm, accessed October 27, 2000
3. Seidenfeld J, Aronson N, Piper MA, et al: Use of erythropoietin for anemia in oncology: Evidence Report/Technology Assessment No 30 (AHRQ Publ No. 01-E009). Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center under Contract No. 290-97-0015. Rockville, MD, Agency for Healthcare Research and Quality, June 2001
4. Seidenfeld J, Piper M, Flamm C, et al: Epoetin treatment for anemia of cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93:1204-1214, 2001
5. Http://oncology.medscape.com/Home/Topics/oncology/oncology.html
6. Cook DL, Guyatt GH, Laupacis A, et al: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102:305S-311S, 1992 (suppl 4)
7. Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2S-4S, 1989
8. American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679, 1996
9. Case DC Jr, Bukowski RM, Carey RW, et al: Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85:801-806, 1993
10. Cascinu S, Fedeli A, Del Ferro E, et al: Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 12:1058-1062, 1994
11. Silvestris F, Romito A, Fanelli P, et al: Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70:313-318, 1995
12. Henry DH, Brooks BJ Jr, Case DC Jr, et al: Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1:252, 1995
13. Kurz C, Marth C, Windbichler G, et al: Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 65:461-466, 1997
14. Oberhoff C, Neri B, Amadori D, et al: Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol 9:255-260, 1998
15. Littlewood TJ, Bajetta E, Cella D, et al: Efficacy and quality of life outcomes of epoetin alfa in a double-blind, placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy. Proc Am Soc Clin Oncol 18:574a, 1999 (abstr 2217)
16. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
17. Fairclough DL, Gagnon D: The significance of missing data in clinical trials. Presented at the International Society for Quality of Life Research conference, October 2000 (abstr 1697)
18. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74, 1997
19. Cella D, Hahn EA, Dineen K: Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Qual Life Res 11:207-221, 2002
20. Markman M, Reichman B, Hakes T, et al: The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 49:172-176, 1993
21. Lavey RS, Dempsey WH: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 27:1147-1152, 1993
22. Dusenbery KE, McGuire WA, Holt PJ, et al: Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 29:1079-1084, 1994
23. Henke M, Guttenberger R, Barke A, et al: Erythropoietin for patients undergoing radiotherapy: A pilot study. Radiother Oncol 50:185-190, 1999
24. Wurnig C, Windhager R, Schwameis E, et al: Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 36:155-159, 1996
25. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al: Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15:174-182, 1998
26. Quirt I, Coutere F, Pichette R, et al: The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy: Results of a randomized, double-blind, placebo-controlled clinical trial. Blood 88:347a, 1996 (abstr 1378)
27. Thatcher N, De Campos ES, Bell DR, et al: Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 80:396-402, 1999
28. Cheung WK, Goon BL, Guilfoyle MC, et al: Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64:412-423, 1998
29. Cheung W, Minton N, Gunawardena K: Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 57:411-418, 2001
30. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
31. Nguyen TV, Trinh GN: Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: Problems of study design and interpretation. J Clin Oncol 20:878, 2002 (letter)
32. Silberstein PT, Witzig TE, Sloan JA, et al: Weekly erythropoietin for patients with chemotherapy induced anemia: A randomized, placebo-controlled trial in the North Central Cancer Treatment Group. Proc Am Soc Clin Oncol 21:356a, 2002 (abstr 1422)
33. Glaspy J, Jadeja JS, Justice G, et al: A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 84:17-23, 2001 (suppl 1)
34. Kotasek D, Berg R, Poulsen E, et al: Randomized, double-blind, placebo controlled, phase I/II dose finding study of Aranesp administered once every three weeks in solid tumor patients. Blood 96:294a, 2000 (abstr)
35. Pirker R, Vansteenkiste J, Gateley J, et al: A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer: NESP 980297 Study Group. Proc Am Soc Clin Oncol 20:394a, 2001 (abstr 1572)
36. Hedenus M, Hansen S, Dewey C, et al: A randomized, blinded, placebo-controlled, phase II, dose-finding study of novel erythropoiesis stimulating protein (NESP) in patients with lymphoproliferative malignancies. Proc Am Soc Clin Oncol 20:393a, 2001 (abstr 1569)
37. Glaspy JA, Jadeja J, Justice G, et al: Randomized, active-controlled, phase 1/2, dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors. Proc Am Soc Clin Oncol 20:387a, 2001 (abstr 1546)
38. Kotasek D, Albertsson M, Mackey J, et al: Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors: Darbepoetin alfa 980291 Study Group. Proc Am Soc Clin Oncol 21:356a, 2002 (abstr 1421)
39. Demetri GD, Kris M, Wade J. et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study-Procrit Study Group. J Clin Oncol 16:3412-3425, 1998
40. Porter JC, Leahey A, Polise K, et al: Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial. J Pediatr 129:656-660, 1996
41. Albitar S, Meulders Q, Hammoud H, et al: Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 10:40-43, 1995 (suppl 6)
42. Kaufman JS, Reda DJ, Fye CL, et al: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis: Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339:578-583, 1998
43. Casadevall N, Nataf J, Viron B, et al: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
44. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 15:1218-1234, 1997
45. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
46. Dammacco F, Castoldi G, Rodjer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172-179, 2001
47. Osterborg A, Brandberg Y, Molostova V, et al: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20:2486-2494, 2002
48. Anonymous: A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes: Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 103:1070-1074, 1998
49. Garton JP, Gertz MA, Witzig TE, et al: Epoetin alfa for the treatment of the anemia of multiple myeloma: A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155:2069-2074, 1995
50. Dammacco F, Silvestris F. Castoldi GL, et al: The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28:127-134, 1998
51. Rose E, Rai K, Revicki D, et al: Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 84:526a, 1994 (abstr)
52. Cazzola M, Messinger D, Battistel V, et al: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 86:4446-4453, 1995
53. Osterborg A, Boogaerts MA, Cimino R. et al: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: A randomized multicenter study-The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 87:2675-2682, 1996
54. Abels R: Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A:S2-S8, 1993 (suppl 2)
55. Abels RI, Larholt KM, Krantz KD, et al: Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1:140-150. 1996
56. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21:21-28, 1994
57. Stasi R, Brunetti M, Bussa S, et al: Serum levels of turnout necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 19:197-201, 1997
58. Kreuzer KA, Rockstroh JK. Jelkmann W, et al: Inadequate erythropoietin response to anaemia in HIV patients: Relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 96:235-239, 1997
59. Takemasa A, Yorioka N, Ueda C, et al: Stimulation of tumour necrosis factor-alpha production by recombinant human erythropoietin may contribute to failure of therapy. Scand J Urol Nephrol 34:131-135, 2000
60. Leon P. Jimenez M, Barona P, et al: Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 30:110-116, 1998
61. Varan A, Buyukpamukcu M, Kutluk T, et al: Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics 103:E16, 1999
62. Sweeney PJ, Nicolae D, Ignacio L, et al: Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Final report of a randomized, open-labelled, phase II trial. Br J Cancer 77:1996-2002, 1998
63. Gamucci T, Thorel MF, Frasca AM, et al: Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 29A:S13-S14, 1993 (suppl 2)
64. Del Mastro L, Venturini M, Lionetto R, et al: Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15:2715-2721, 1997
65. Welch RS, James RD, Wilkinson PM, et al: Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1:261, 1995
66. Moher D, Pham B, Jones A, et al: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609-613, 1998
67. Schulz KF, Chalmers I, Hayes RJ, et al: Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412, 1995